Iridex Q2 revenue falls 7% to $12.6 million; net loss widens to $1.3 million
Iridex reported second-quarter 2026 revenue of $12.6 million, down 7% from a year earlier, as lower retina sales outweighed growth in its Cyclo G6 glaucoma products. The net loss widened to $1.3 million, or $0.07 per share, from $1.0 million, or $0.06 per share, and the company reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million.
Key points
- Total revenue was $12.6 million, compared with $13.6 million in the prior-year quarter; retina product revenue fell to $6.5 million from $8.0 million.
- Cyclo G6 product family revenue rose 19% to $3.9 million, with 17,700 probes sold versus 13,100 a year earlier.
- Net loss was $1.3 million, or $0.07 per share, versus $1.0 million, or $0.06 per share, in the second quarter of 2025.
- Full-year 2026 revenue guidance of $51 million to $53 million was reaffirmed; adjusted operating expense guidance is $19 million to $19.5 million.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.